Sunday, 22 July 2018 - 13:33
  • it
  • de
  • en
  • fr

Valeant Pharmaceuticals

H1 record-results for M&A pharmaceutical activity

The pharmaceutical industry has recently undergone a sea change: indeed, in H1 2018, the M&A transaction volume rose to 1893, that is an increase of 128 transactions compared to H1 2017. Transaction value went from da $209bn (H12017) to $238bn…

Valeant’s shares plunge as FDA refuses to approve key treatment

Valeant announced today, before Wall Street opened, that FDA has not approved Duobrii (halobetasol propionate and tazarotene), for the treatment of plaque psoriasis. The refusal is not due to a lack of information or an incomplete application, but only to…

Valeant plunges: capitalization down 11% following Q4 2017 results

Canada-based Valeant has had the worst start today. The group led by CEO Joe Papa announced today, before trading started, its Q4 2017 results, which were below analysts’ and investors’ expectations. The company’s shares soon reacted with a 11% decline…

US groups stronger and more competitive thanks to fiscal reform

The JP Morgan Healthcare Conference, which has just ended in San Francisco, has given analysts an opportunity to analyze the different views of big pharma companies’ CEOs . The fiscal reform proposed by the Trump administration has been a widely-debated…

Valeant’s unstoppable rise: +50% since January 2017

Valeant has become trading leader: the Canada-based group’s shares, indeed, have risen 50% since earlier this year, especially thanks to the new CEO Joseph Papa, who reportedly has gained investors’ and shareholders’ trust. Valeant’s management has recently shared exclusively positive…

Valeant surprises everyone with amazing quarter

Canada-based Valeant has surprised analysts and investors with a highly positive third quarter and its shares (Wall Street) soon reacted with a sharp +16% as trading opened. The debt built up by former CEO Micheal Pearson decreased by as much…

Valeant sells Sprout Pharmaceuticals, producer of Female Viagra

Valeant Pharmaceuticals announced today before Wall Street opened that it has sold  Sprout Pharmaceuticals to the same shareholders from which it acquired it two years ago for $1bn. Sprout has developed Addyi, the controversial therapy to stimulate female libido, which…

Positive signs from Valeant, market rewards it

Valeant seems to have partially won back trust from analysts and investors. This was proved by its shares leaping by 10% yesterday when Wall Street opened – definitely a considerable step forward for the company, whose capitalization plunged from $90bn…

Valeant sells Obagi Medical to Chinese fund for $190m

Valeant Pharmaceuticals today announced it entered into an agreement to sell Obagi Medical Products to China-based fund Haitong International Zhonghua Finance Acquisition for $190m in cash. Obagi Medical, headquartered in Long Beach, California, focuses on developing dermatological and plastic surgery…

Ambitious growth plan for India-based Lupin

India-based drugmaker Lupin was granted final approval by FDA to commercialize the generic drug to Valeant’s Ancobon (flucitosine), a treatment for Candida and Cryptococcus infections. Ancobon generated $46.5m in sales in the US in 2016. Lupin is a strongly growing…

Valeant sells iNova to PEP and Carlyle funds for $930m

Valeant announced to investors that it sold Australian subsidiary iNova to hedge funds Pacific Equity Partners and Carlyle Group for $930m. Valeant acquired iNova for AUS$650m in 2011. Over the years, iNova became a market leader in Australia and South…

Valeant in talks to sell Bausch&Lomb’s Surgical Products business

Valeant Pharmaceuticals is reportedly in talks to sell Bausch&Lomb’s Surgical Products business to Germany-based Carl Zeiss Meditec AG. The news was reported today by Bloomberg, which added that the divestiture is likely to fetch Valeant $2bn. Valeant’s shares (Wall Street)…

Valeant reportedly on the path of recovery

Valeant management announced at today’s investor day that it expects to launch at least 50 products in 2017, which will together generate sales of more than $100m. Investors received another positive announcement yesterday, as CEO Joe Papa informed that the…

Bids for Valeant’s Inova not meeting expectations

Valeant Pharmaceuticals, owner of iNova, is reportedly dissatisfied with the three bids it has so far received for its subsidiary. It is believed that offers have come in at around AUD900m (USD 686.5m), below the expected minimum of one billion…

Private equity consortium tries to acquire Valeant’s iNova

Private equities Pacific Equity Partners and The Carlyle Group are likely to create a consortium targeting the acquisition of iNova Pharmaceuticals. iNova was acquired by Valeant in 2011 for AUD6250m and could now be sold for AUD1bn, experts say. (Source:…

Valeant-Takeda’s $10bn deal to sell Salix fails

Valeant renounced to sell its gastrointestinal business unit Salix to Takeda for $10bn. Indeed, talks between the groups reportedly failed, since Valeant is reluctant to provide financial details about Salix. Shares in Valeant instantly lost nearly 9%, which proves that…

Investment funds target Valeant’s iNova (AUD1bn)

US investment fund KKR seems to be targeting Australia-based iNova, owned by Valeant group, The Australian Financial Review reports. KKR, indeed, is allegedly about to initiate acquiring iNova, valued at least AUD1bn. The newspaper also mentions Pacific Equity Partners and…

Takeda ready to acquire Valeant’s Salix for $10bn

Japan-based Takeda is reported to be in advanced talks with Valeant to acquire Salix Pharmaceuticals. The rumors started circulating yesterday night, when Valeant’s management confirmed ongoing talks about Salix. Valeant’s shares soon rose by almost 30%, even though selling Salix…

Valeant doesn’t rule out selling Bausch & Lomb

Valeant CEO Joseph Papa has told in an interview to CNBC he is not ruling out selling the subsidiary Bausch & Lomb. Valeant has reached over $30bn of debt and has lost over 90% of market capitalization in the last…